The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
Open accessAbstract
Alzheimer's disease (AD) is characterized by enhanced β-amyloid peptide (βA) deposition along with glial activation in senile plaques, selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain damage in vivo. This background prompted us to study the localization, expression, and function of cannabinoid receptors in AD and the possible protective role of cannabinoids after βA treatment, both in vivo and in vitro. Here, we show that senile plaques in AD patients express cannabinoid receptors CB 1 and CB 2, together with markers of microglial activation, and that CB 1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that G-protein coupling and CB 1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein nitration is increased, and, more specifically, CB 1 and CB 2 proteins show enhanced nitration. Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent βA-induced microglial activation, cognitive impairment, and loss of neuronal markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block βA-induced activation of cultured microglial cells, as judged by mitochondrial activity, cell morphology, and tumor necrosis factor-α release; these effects are independent of the antioxidant action of cannabinoid compounds and are also exerted by a CB 2-selective agonist. Moreover, cannabinoids abrogate microglia-mediated neurotoxicity after βA addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.
McCarthy, K. D., & de Vellis, J. (1980) · The Journal of cell biology · doi:10.1083/jcb.85.3.890 · Cited by 3,845
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., & Perry, G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02653.1997 · Cited by 1,239
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 2×
“Furthermore, the involvement of CB1 receptors and their endogenous ligands as neuroprotectants has been demonstrated recently in CB1-null mutants, which are more susceptible to neurodegeneration (Parmentier-Batteur et al., 2002; Marsicano et al., 2003).”
BackgroundGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. L. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 869
McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 680
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Barger, S. W., Hörster, D., Furukawa, K., Goodman, Y., Krieglstein, J., & Mattson, M. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9328 · Cited by 631
Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 624
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587 · cited 2×
“However, it has been recognized recently that removal of A by activated microglia may be beneficial (Bard et al., 2000; Wyss-Coray et al., 2001; Jantzen et al., 2002).”
BackgroundEvidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Di Marzo, V., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 541
Glass, M., Dragunow, M., & Faull, R. L. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00008-7 · Cited by 483
Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures
Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., & Greenberg, D. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02987.1999 · Cited by 468
Structure−Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists
Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., McCallion, D., Pertwee, R., & Makriyannis, A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980363y · Cited by 447
Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons
Gao, H.-M., Hong, J.-S., Zhang, W., & Liu, B. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00782.2002 · Cited by 439
Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques.
Dickson, D. W., Farlo, J., Davies, P., Crystal, H., Fuld, P. A., & Yen, S. H. (1988) · PubMed · Cited by 427
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez, C., CEBALLOS, M. L. D., del Pulgar, T. G., Rueda, D., Corbacho, C., Velasco, G., Galve‐Roperh, I., Huffman, J. W., y Cajal, S. R., & Guzmán, M. (2001) · Cancer Research · Cited by 422
Self-citationMolina-Holgado, E., Vela, J. M., Arévalo-Martı́n, A., Almazán, G., Molina-Holgado, F., Borrell, J., & Guaza, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09742.2002 · Cited by 419
Herrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392
Skaper, S. D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., & Leon, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3984 · Cited by 377
Masliah, E., Sisk, A., Mallory, M., Mucke, L., Schenk, D., & Games, D. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-18-05795.1996 · Cited by 370
Weldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O’Hare, E., Esler, W. P., Maggio, J. E., & Mantyh, P. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02161.1998 · Cited by 348
Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., Morgan, D., & Gordon, M. N. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02246.2002 · Cited by 340
Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., & Behl, C. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00716.x · Cited by 315
MULLER, U. (1994) · Cell · doi:10.1016/0092-8674(94)90066-3 · Cited by 306
Huffman, J. W., Liddle, J., Yu, S., Aung, M. M., Abood, M. E., Wiley, J. L., & Martin, B. R. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00219-9 · Cited by 288
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
Vodovotz, Y., Lucia, M. S., Flanders, K. C., Chesler, L., Xie, Q. W., Smith, T. W., Weidner, J., Mumford, R., Webber, R., Nathan, C., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1425 · Cited by 288
Westlake, T. M., Howlett, A. C., Bonner, T. I., Matsuda, L. A., & Herkenham, M. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90511-8 · Cited by 283
Δ9‐Tetrahydrocannabinol induces apoptosis in C6 glioma cells
Sánchez, C., Galve-Roperh, I., Canova, C., Brachet, P., & Guzmán, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01085-0 · Cited by 280
Self-citationCannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide
Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., & Leon, A. (2003) · Glia · doi:10.1002/glia.10177 · Cited by 275
Xie, Z., Wei, M., Morgan, T. E., Fabrizio, P., Han, D., Finch, C. E., & Longo, V. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03484.2002 · Cited by 272
Cannabinoid Receptor Agonists Protect Cultured Rat Hippocampal Neurons from Excitotoxicity
Shen, M., & Thayer, S. A. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.3.459 · Cited by 250
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells
Puffenbarger, R. A., Boothe, A. C., & Cabral, G. A. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1<58::aid-glia6>3.0.co;2-w · Cited by 248
Iravani, M. M., Kashefi, K., Mander, P., Rose, S., & Jenner, P. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00562-0 · Cited by 247 · cited 1×
“, 2002) and in vivo (Weldon et al., 1998; Herrera et al., 2000; Iravani et al., 2002) paradigms.”
Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice
Parmentier-Batteur, S., Jin, K., Mao, X. O., Xie, L., & Greenberg, D. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09771.2002 · Cited by 225
Waksman, Y., Olson, J. M., Carlisle, S. J., & Cabral, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38093-0 · Cited by 222
Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain
Breivogel, C. S., Sim, L. J., & Childers, S. R. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36967-8 · Cited by 202
van der Stelt, M., Veldhuis, W. B., Bär, P. R., Veldink, G. A., Vliegenthart, J. F. G., & Nicolay, K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06475.2001 · Cited by 176
Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors
MacLennan, S. J., Reynen, P. H., Kwan, J., & Bonhaus, D. W. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701915 · Cited by 175
Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells
Bouaboula, M., Bourrié, B., Rinaldi-Carmona, M., Shire, D., Fur, G. L., & Casellas, P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.23.13973 · Cited by 175
Gómez del Pulgar, T., de Ceballos, M. L., Guzmán, M., & Velasco, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205797200 · Cited by 169
Self-citationFibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease
Matsuoka, Y., Picciano, M., LaFrancois, J. J., & Duff, K. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00115-4 · Cited by 166
Neuroprotective and neurorestorative strategies for Parkinson's disease
Dawson, T. M., & Dawson, V. L. (2002) · Nature Neuroscience · doi:10.1038/nn941 · Cited by 163
A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain
Ong, W.-Y., & Mackie, K. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00025-1 · Cited by 146
In vitro aggregation facilitates β-amyloid peptide-(25–35)-induced amnesia in the rat
Delobette, S., Privat, A., & Maurice, T. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00922-3 · Cited by 143
Tan, J. R., Town, T., Mori, T., Wu, Y., Saxe, M., Crawford, F., & Mullan, M. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-20-07587.2000 · Cited by 138
Aoyama, K., Matsubara, K., Fujikawa, Y., Nagahiro, Y., Shimizu, K., Umegae, N., Hayase, N., Shiono, H., & Kobayashi, S. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<524::aid-ana19>3.0.co;2-5 · Cited by 131
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide
Milton, N. G. N. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00936-9 · Cited by 125
UTTENTHAL, L. O., Alonso, D. C., Fernández, A. P., Campbell, R. O., Moro, M. Á., Leza, J. C., Lizasoaín, I., Esteban, F. J., Barroso, J. B., Valderrama, R., et al. (1998) · Microscopy Research and Technique · Cited by 123
Lee, S. C., Zhao, M., Hirano, A., & Dickson, D. W. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199911000-00006 · Cited by 112
Indomethacin Reverses the Microglial Response to Amyloid β-Protein
Netland, E. E., Newton, J. L., Majocha, R. E., & Tate, B. A. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00047-5 · Cited by 94
Fernández-Tomé, P., Brera, B., Arévalo, M., & CEBALLOS, M. L. D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.006 · Cited by 94
Romero, J., Berrendero, F., García-Gil, L., de la Cruz, P., Ramos, J. A., & Fernández‐Ruíz, J. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00552-6 · Cited by 86
Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity
Hampson, A. J., & GRIMALDI, M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01536.x · Cited by 56
Mato, S., & Pazos, Á. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.004 · Cited by 56
Relationship between β-AP peptide aggregation and microglial activation
Casal, C., Serratosa, J., & Tusell, J. M. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03362-5 · Cited by 42
Sáez‐Valero, J., CEBALLOS, M. L. D., Small, D. H., & Felipe, C. D. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00282-3 · Cited by 35
Pavía, J., Alberch, J., Alvárez, I., Tolédano, A., & CEBALLOS, M. L. D. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00900-3 · Cited by 33
Cited by
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Senile plaques in AD patients express both CB1 and CB2 receptors together with markers of microglial activation, and CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation (Ramirez et al., 2005).”
BackgroundInfluentialAmyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Metadata
- Authors
- Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & de Ceballos, M. L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2005-02-23
- Volume
- 25
- Issue
- 8
- Pages
- 1904-1913
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2028794471
- Cited by
- 785
- References
- 69
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.